Name: Allopurinol
Brand: Selleck Chemicals
SKU: S1630
Availability: InStock
Rating: 5 (19 reviews)

Jump to

Quality Control

Batch: Purity: 99.98%

99.98

Related Targets	PD-1/PD-L1 CXCR STING AhR Immunology & Inflammation related CD markers Interleukins Anti-infection Antioxidant COX
Other ROS Inhibitors	Piperlongumine MitoQ (Mitoquinone) Mesylate H2DCFDA (DCFH-DA) Neohesperidin Carnosic acid Gallic acid (20R)Ginsenoside Rg3 Pyrogallol Idebenone Asiaticoside

Solubility

In vitro
Batch:

DMSO : 27 mg/mL (198.36 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 3 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	136.11	Formula	C₅H₄N₄O	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	315-30-0	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			Smiles	C1=NNC2=C1C(=O)NC=N2

Mechanism of Action

Targets/IC₅₀/Ki	xanthine oxidase
In vitro	Allopurinol reverses the increased xanthine oxidase activity in ischemia-reperfusion injury of neonatal rat hearts. This compound (10 mM) treatment suppresses xanthine oxidase activity induced by hypoxia-reoxygenation injury and the production of reactive oxygen species. It also decreases the concentration of intracellular Ca2+ increased by enhanced xanthine oxidase activity.
In vivo	Allopurinol shows abnormal pyrimidine metabolism together with renal toxicity which could be ameliorated by uridine, indicating that this compound essentially causes pyrimidine metabolism abnormality leading to renal impairment in normal mice. It increases urinary OD excretion to an extent similar to that in normal mice administered the same dose of this chemical in DNFB-sensitized mice. This compound promotes a clinical improvement which is accompanied by a reduction in the parasitic load in the blood, skin and lymph nodes but, even after long period of allopurinol administration alone, Leishmania may persist in dog tissues in Leishmania-infected dogs. It prevents early alcohol-induced liver injury in rats, most likely by preventing oxidant-dependent activation of NF-kappaB. This chemical protects dose-dependently against acetaminophen-induced cell injury, the loss of ATP and the increase of the GSSG content in the total liver and in the mitochondrial compartment without inhibiting reactive metabolite formation in mice. It almost completely inhibits hepatic xanthine oxidase and dehydrogenase activity, but only high doses prevents the increase of the mitochondrial GSSG content.
References	[1] https://pubmed.ncbi.nlm.nih.gov/16516885/ [2] https://pubmed.ncbi.nlm.nih.gov/10823345/ [3] https://pubmed.ncbi.nlm.nih.gov/17553711/ [4] https://pubmed.ncbi.nlm.nih.gov/10734182/ [5] https://pubmed.ncbi.nlm.nih.gov/2262912/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05665699	Recruiting	Gout	InventisBio Co. Ltd	April 17 2023	Phase 2
NCT05193838	Unknown status	Dilated Cardiomyopathy	Assiut University	May 1 2022	--
NCT05360628	Completed	Healthy	InventisBio Co. Ltd	November 1 2021	Early Phase 1
NCT04853615	Not yet recruiting	SGLT2i Kideny Protection Against Contrast in Diabetic Kidney	Fayoum University\|Cairo University	July 1 2021	--

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Allopurinol ROS inhibitor

Chemical Structure

Molecular Weight: 136.11